Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography-Reference-Cited by-同舟云学术

Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

Published:2018-04-04 Issue:8 Volume:14 Page:989-997
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Mielke Michelle M.¹²,Hagen Clinton E.³,Xu Jing⁴,Chai Xiyun⁴,Vemuri Prashanthi⁵,Lowe Val J.⁵,Airey David C.⁴,Knopman David S.²,Roberts Rosebud O.¹²,Machulda Mary M.⁶,Jack Clifford R.⁵,Petersen Ronald C.¹²,Dage Jeffrey L.⁴

Affiliation:

1. Division of EpidemiologyDepartment of Health Sciences ResearchMayo ClinicRochesterMinnesotaUSA

2. Department of NeurologyMayo ClinicRochesterMNUSA

3. Division of Biomedical Statistics and InformaticsDepartment of Health Sciences ResearchMayo ClinicRochesterMinnesotaUSA

4. Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisINUSA

5. Department of RadiologyMayo ClinicRochesterMNUSA

6. Department of Psychiatry and PsychologyMayo ClinicRochesterMNUSA

Funder

U.S. Department of Defense

GE Healthcare

Avid Radiopharmaceuticals

National Institutes of Health

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2018.02.013

Reference34 articles.

1. Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

2. The projected effect of risk factor reduction on Alzheimer's disease prevalence

3. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

4. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

5. Cerebrospinal fluid tau and ptau 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Cited by 435 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of prognosis in Alzheimer’s disease: The role of cognitive dysfunction, immune abnormalities, and advanced neuroimaging;World Journal of Clinical Cases;2024-09-26

2. Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications;Neurology and Therapy;2024-09-07

3. Clinical significance of plasma candidate biomarkers of Alzheimer’s Disease;Neurologia i Neurochirurgia Polska;2024-08-28

4. Characterization of Ptau181 Among a Diverse Community-Based Cohort: A HABS-HD Study;Journal of Alzheimer's Disease;2024-08-20

5. Combined Serum Total Tau-Neurofilament Light Polypeptide Could be Used as Screening Biomarkers For Alzheimer’s Disease;2024-08-18